A heating and freezing process known as dual thermal ablation can kill pancreatic cancer cells, according to new research from Binghamton University, State University at New York.
The collaborative study, conducted by researchers from academia and industry and funded by grants from the National Cancer Institute, used pancreatic cancer cells to investigate the effect of heating and freezing on cell death. The research was conducted by Robert Van Buskirk and John Baust, professors of biological sciences and directors at Binghamton University’s Institute of Biomedical Technology, and Kenneth Baumann, a graduate student studying biology.
“How do we solve the problem of pancreatic cancer when it comes to trying to get rid of the tumor, when chemo and radiation just simply doesn’t work?” said Van Buskirk. “The whole idea is, can one come up with a different surgical intervention that’s less invasive and more effective?
“In order to figure that out, you can commercially obtain pancreatic cancer cells and grow them on specialized plasticware,” Van Buskirk said. “The basic question is, are both freezing and heat in combination more effective than freezing or heat alone? If you freeze pancreatic cancer cells like you do in cryoablation, a lot of them die, but some will survive and regrow. If you heat them, they’ll die, but again some will come back. But with dual-thermal ablation, for reasons that we do not yet understand, more die and don’t come back. In fact, over time, cells that survive the initial insult continue to die.”
“What we’ve observed is that we are able to achieve complete cell death using a combination of heating and then freezing at temperatures that alone would not be lethal to kill pancreatic cancer cells,” said Baumann.
Researchers heated and froze cancer cells and looked at the effect, using various technologies to determine the level of cell death, on regrowth as well as which cell stress pathways were activated.
“Using a variety of assays, we are able to determine the initial level of cell death as well as to what extent the surviving population is able to regrow,” Baumann said. “We were also able to determine the specific paths of cell death activated as a result of the dual thermal exposure.”
“When cells are disturbed—which means they are frozen or they see heat—various cell stress pathways are activated,” said Van Buskirk. “The interesting thing about cells, especially cancer cells, is that they will activate pathways to protect themselves. The objective of this line of molecular-based research is to find out which stress pathways are activated in pancreatic cancer cells so that we can better understand why dual-thermal ablation appears to be more effective.”
“Current studies are focused on elucidating which stress pathways specifically cause these cells to die or what is keeping them alive. That way, we can optimize this treatment to be as effective as possible against pancreatic cancer,” Baumann said.
According to Van Buskirk, modulating these stress pathways is the key to making the heating and freezing ablation process more effective. This could lead to the development of a new way to remove cancerous pancreatic tumors.
In addition to the cell molecular research, several members of the study team are working on developing new catheter technologies to deliver this ablative therapy to patients. “If a very thin catheter can be developed to target the tumor, and if we understand how pancreatic cancer responds to ablation at the molecular level, then we may be able to develop a new therapy to approach something that has been completely unapproachable, the targeted killing of a tumor in a very difficult place: the pancreas,” said Van Buskirk.
The Latest on: Pancreatic cancer
Postmenopausal calcium channel blocker use tied to pancreatic cancer risk
on April 18, 2018 at 11:03 am
Researchers reviewed data for 145,551 postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative from 1993 to 1998 and found that those who had ever used short-acting calcium channel blockers had a 66% greater risk of pancreatic ... […]
Blood pressure meds linked to higher pancreatic cancer risk in postmenopausal women
on April 18, 2018 at 9:38 am
A class of blood pressure medications—short-acting calcium channel blockers (CCBs)—was associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented April 17 at the American Association for Cancer ... […]
Specific Type Of Blood Pressure Drug Increases Risk Of Pancreatic Cancer In Postmenopausal Women
on April 18, 2018 at 7:25 am
18 April 2018, 9:57 am EDT By Rubi Valdez Tech Times Sign up for our email newsletter today. Tech Times' biggest stories, delivered to your inbox. […]
Calcium Channel Blockers May Up Pancreatic Cancer Risk in Women
on April 18, 2018 at 7:19 am
HealthDay News — Use of short-acting calcium channel blockers (CCBs) is associated with increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the annual meeting of the American Association for Cancer Research ... […]
MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting
on April 18, 2018 at 6:11 am
Dr. Maffuid's presentation summarized results from the first cohort of three patients treated in the Phase 1 clinical trial of the Company's MVT-1075 radiopharmaceutical product in late stage pancreatic cancer. These results at the initial dose support a ... […]
Attention women: Your choice of blood pressure medicine may affect your risk of pancreatic cancer
on April 18, 2018 at 2:10 am
In findings with potentially broad implications for the public's health, new research has found that some women who treat their high blood pressure with a class of drugs that relaxes the blood vessels were more likely to develop pancreatic cancer than ... […]
Some blood pressure meds tied to pancreatic cancer risk in women
on April 17, 2018 at 6:26 pm
TUESDAY, April 17, 2018 -- Certain drugs prescribed to treat high blood pressure may boost a woman's risk for developing pancreatic cancer after menopause, new research suggests. In a large study of postmenopausal women, those who had ever taken a short ... […]
Short-Acting CCBs May Increase Risk of Pancreatic Cancer
on April 17, 2018 at 2:23 pm
A large observational study found that use of short-acting calcium channel blockers (CCBs) for hypertension is associated with increased incidence of pancreatic cancer among postmenopausal women, when compared with the use of other types of ... […]
Short-acting calcium channel blockers were associated with increased risk of pancreatic cancer in postmenopausal women
on April 17, 2018 at 7:17 am
Calcium channel blockers (CCBs), specifically the short-acting form of CCBs, which are prescribed to treat high blood pressure, were associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the AACR ... […]
Cancer risk found to be three times greater after acute thrombosis in the leg
on April 16, 2018 at 6:30 pm
"It is especially, but not only, the smoking-related forms of cancer that show up after the arterial thrombosis. The risk is highest for lung and pancreatic cancer, both of which are related to smoking. However, other forms of cancer such as colon cancer ... […]
via Google News and Bing News